Page last updated: 2024-10-30

metformin and Sarcoma 180

metformin has been researched along with Sarcoma 180 in 1 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Sarcoma 180: An experimental sarcoma of mice.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Yang, Q1
Zhang, T1
Wang, C1
Jiao, J1
Li, J1
Deng, Y1

Other Studies

1 other study available for metformin and Sarcoma 180

ArticleYear
Coencapsulation of epirubicin and metformin in PEGylated liposomes inhibits the recurrence of murine sarcoma S180 existing CD133+ cancer stem-like cells.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2014, Volume: 88, Issue:3

    Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Ce

2014